Earnings Call: Q2 2021

Aug 19, 2021

Good day, ladies and gentlemen, and welcome to your Pressure Biosciences Second Quarter Investor Conference Call. All lines have been placed in a listen only mode and the floor will be open for your questions and comments following the presentation. At this time, it is my pleasure to turn the floor over to your host, Rick Schumacher. Sir, the floor is yours. Thank you, Melinda, and thanks, everybody, for joining us today for our second quarter financial review and business update. Before we begin, as always, I need to read a short cautionary statement. The following remarks may constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such factors include, among others, those detailed from time to time in the company's filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which such statement is based. First of all, as always, I'm pleased to welcome everybody on this call. I'm especially pleased because I get to welcome a new voice, on our investor call today, and this is the voice of John Hollister. John has worked, with a number of people over the years and and number of companies that that I I know and and and came extremely well recommended from from many of them. I've known him in the biotech and pharma space, as I said, for many years. He's worked with startups all the way to billion dollar Goliath. So he's been very successful in those positions over the years. He's just sold his last company about two years ago in which he was the CEO. And while waiting to start his next adventure, I asked him for a little help. This is back in February. He said yes, and he gave us some part time help, particularly in the marketing and sales area. And then in October 2020, we lost our director of sales and marketing. And I asked John if he'd come on board full time because he still was thinking about his new adventure and hadn't started yet. And and to my delight, he agreed. And as I say, the rest is history. All one needs to do is take a look at our results for the first and second quarter. This is the second best back to back quarter in PBI's history. Of course, I asked John why it wasn't the best back to back, but that's a different story. But it's the second best back to back quarter we've had in our entire history. And as I say, it's just the tip of the iceberg. So before we begin, John, I'd like to just welcome you up on the microphone and please tell our listeners just a minute or so of your background. That would be helpful. Hey, Rick. Thank you so much, and it's really a pleasure to be speaking to your investors. So just for background, Rick touched on it, but I can't believe that more than thirty years have passed since I graduated from Stanford and went into big pharma at Smith Klein where I was in a series of sales and marketing roles. And that's why I started predominantly in vaccines, biologics, and I got a chance to launch a vaccine and also started Salesforce in The UK. Left there after eight years and looked at Amgen to help launch an oncology product called Neulasta, which did about a billion in its first year. And I was made the global commercial lead in oncology, the first of those people, and got to help develop a number of different assets. But after fifteen years of big companies, I decided, like some of my friends, to go off and try the start up world. And so I've spent the last seventeen years in leadership roles, including CEO of several pharmaceutical, medical device, and diagnostics companies, both public and private. He got a lot of experience in doing that. And as Rick mentioned, couple of years ago, I'd already known Rick for a few years, and I had watched a few bio question of biosciences. Just fascinated by the technology and sounded like you needed a little help initially commercializing ultra sheer technology. And but since then, you know, I just fall in love with all three platforms and very excited about where this company is because it really is a transformational period. And the addition of Agrochem is just icing on the cake. So with that, I'll pass it back to Rick. Hey. Thanks, John. And I think everybody after listening to that can see why we're so excited to have you on board. This is transfer transformational. This is quite a transformational year. We are we have so many things in the hopper. It's only gonna get better in our opinion. Take a look at, you know, what we've been doing so far and then think about UltraShear coming out. Erifold is starting to catch fire. And, of course, the Agrochem, as you mentioned, that you've been a great help on for with me, which I appreciate. So all of these things are coming to fruition over the coming weeks, months, and and by early next year. So a guy like you is gonna be very helpful to our company and to our investors to with your experience. So as you know, I I keep I I hate to say it, but I keep praying that your next adventure doesn't start too soon because we need you here at PBIO. So for today's meeting, we're going start with a very brief discussion of the second quarter results, and then we'll highlight some of the accomplishments so far in this year, and then we're going to open it up for Q and A. On the financial side, of course, we have sent out the finances both in the Q and in a press release. There's no need to go through them in detail. I'm always available after the call. You guys know how to reach me to take any questions you have, but it would be a shame not to highlight some of the terrific things that have happened both in the second quarter and the year to date. So just like the first quarter, we had a very strong second quarter. Our revenue was over $600,000 and it was up 127% over last year. Our instrument sales led the way up 178%. Our consumable sales were down 14%, but they started picking up right at the end of the quarter. So we're not concerned. And of course, for the year so far, they're they're they're up a lot. So, Barefold and UST, which right now is primarily Barefold and it's a service and it's up 298% over last year and, it's up over the first quarter and it's just it's starting to catch fire. Our operating loss, you look at all these things and then you look and see that the operating loss went down over 50%, it's just icing on the cake. So we have a very strong across the board revenue increase, a lot of calls, lot of desire for our products and our pressure based core business. And at the same time, we reduced our operating loss from $1.3 down to $646,000 for the second quarter and from $2,700,000 down to 1,700,000.0 for the first half. So we're certainly headed in the right direction. And the numbers are just as good for the year to date because of the good first quarter. So again, once you look at them, if you have any questions either at the end of our brief prelude to the Q and A or any time after, give me a call. I'll be happy to go through them. In terms of operational and technical highlights, we not only had a very strong quarter financially, but we had a very strong quarter operationally and on our technical business. We formed a new subsidiary in July called PBI Agrochem. We feel we have business that we can get into in the agrochemical space where I just saw today another chemical has been banned by the e p by the EPA for use in in on on on crops that are going into food. We just we put too many chemicals into our food. We put too many chemicals into our land, and we're looking at eco friendly agrochemicals as everyone knows. With UltraShear technology, we can we can make these good products even better. So we're not only gonna be developing our own products, we're we're working on the on the acquisition of an existing product line that's sort of been off the market for a couple of years, and we're going to bring it back on. Terrific product line that has a following, but just like new improved Tide, we can have new improved agrochemicals. Our UltraShear is going to play a big role in this. About half of the chemicals, agrochemicals, if not more, are oil based, and that's where a nanoemulsification really helps. You can apply less and get a better effect in most cases. And speaking of nano emulsification, over the last three months, three to six months, we received three new patents that everybody knows for our UltraShear technology, which is the platform behind the nanoemulsification. And so, we're very excited about this. We announced a million over a million dollars in orders in the first month of of setting up Agrochem. We've we've now rented a a site out west where we'll be doing the the warehousing processing and packaging. We've already got a full time employee. We already expect the first half a million dollars of bulk material that needs to come in and and get processed and shipped out to happen this week or early next week, probably this week. So we are in the business. The agrochemical business is a multibillion dollar business, but what's really needed there are green eco friendly compounds and and compounds that we can use less of and get and make them go further. And so we're very excited about what we're gonna do in that space. John has been an enormous help because of his background. He and I have been working as a team on a lot of things so that you can be assured it's it's it's gonna happen most likely because not only is it on my shoulders, but it's also on John's shoulders. And he's got terrific background as you've already heard. And so whether it's the agrochemical launch or it's ultra sheer technology or even Perifold, we pulled John into all three of those areas. And and he's been a a help over the last few months as a full time actually, six months as a full time employee. Great. I just had a couple of cup a couple of thoughts on the agri agri chem business because I I'm very excited about it. I actually grew up in an avocado ranch, and my grandfather or grandmother were very large citrus growers. And so I'm very familiar firsthand with the agribusiness and the complexities of pesticides and fertilizers and actually our product enhancers. And these products are truly eco friendly, revolutionary, but doing fact many of them employ different kinds of oils, natural oils, but they are effective in doing what they do, but they separate like your oil and vinegar does. And so, yep, growers, whomever is handling the product, has to spend time in making certain that these thousand liter totes are mixed very thoroughly. And when I say time, it can be upwards of an hour and twenty minutes with a little propeller in it. And if it sits, that product sits for any period of time before it's dispensed, you have to restir it. If if we make a manual motion of that, that eliminates that step, or it has the potential to do so, which could be huge in addition to, as Rick said, likely offer better penetration into the leaves or into the soil or more effective in terms of encouraging bugs to leave, which are all the goals of the Agrochem. What's been fascinating because we've also spent some time on the CBD side and the cannabis side is the potential use in in the cannabis world for exactly the same reasons. And so there's a great deal of synergies that are appearing in work that we've already been doing that will apply from the agrochem world. Awesome. Thank you, John. And so at this point, I think one or two more of the to acknowledge one or two more of the great things happened in the last four or five months. We reported on the successful NanoMultification using our UltraShear technology of a compound called astaxanthin. Astaxanthin is basically accepted by almost everybody out there that I know as one of the world's most potent, some people say the most potent antioxidant. But it comes out of algae and it's an oil. It's in an oil. So like many other things that are oil based, we as humans and our pets, we're water based, so oil based compounds don't get absorbed very well. So we we looked at astaxanthin. We looked at CBD. We looked at many other oil based compounds, and our UltraShear technology has been successful at nanoemulsifying and basically turning the oil drops into millions, if not billions of tiny little nano sized oil droplets. And therefore the active ingredient gets spread among millions if not billions of nano sized oil droplets. And that allows it to become dissolved in water in our bodies and transported throughout the body and allows the body to extract from that oil those oil droplets very quickly the active ingredient. So the the the general concept is that with a nano emulsion, you can generally get what's called bioavailability greater than 90%, that the active ingredient is available to to the body in 90% or more. Whereas with a macro or micro emulsion such as your raspberry vinaigrette, you know, which doesn't mix very well, the the amount of, absorption is down to it's 6%, ten %, twelve %. So as John said, you know, we can use less and and get and make it go further. So we're excited. John, you've been, John's been talking to three or four companies about astaxanthin in particular and, has has, taken that off of the my table and has led discussions with some of the leading companies in the world with astaxanthin. We're not here to announce anything, but John, can you give us an idea? You're getting a lot of phone calls from people that are interested in UltraShear in multiple different areas. Correct? Absolutely. And the response is instantaneous from some of the biggest players in the industry. I think the first element is this nanotechnology allows an opaque and otherwise opaque liquid like astaxanthin or CBD, and it turns it absolutely clear. We can when the particle size gets so small, it no longer reflects light. The the applications for CBD and astaxanthin are two examples, but the applications in pharmaceuticals, in nutraceuticals, in food processing, as as well as the agrochemical side are just the tip of the iceberg. There are so many directions we can go, whether it's very high value small volumes or much larger volumes. And so, you know, we're looking at processing a couple liters of fluid in a minute, which is fairly large volume of anything, but it gives you a a very concentrated solution that you could then infuse any of these into a second product, for instance, a beverage, whether it's an antioxidant like astaxanthin or a kind of broad use product like a CBD. It's based on the the list of potential customers who can utilize our technology is remarkable. And so we're balancing that as a smaller organization, but it's great to have the demand that's pulling us along. Right before I turn it over now to Q and A, I just one more thing. I gave a talk, a short talk yesterday at something called Emerging Growth, and I believe it's out on YouTube now, and you can see the fifteen minutes. But the bottom line here is we should all understand that this is a transformational year, that the revenue that we've seen, which is now a double more than double than what we saw last year, two terrific back to back in our core products, we're going to it's going to be additive now starting in the third quarter with our agrochemical products. Our BeraFold is already growing. And at the end of the year or early next year with our old Keshire products. So it's exciting time now for Pressure Bio and for our investors. So at this point, Melinda, I'd like to turn it over to our guests and take any questions if there are any. Thank you. The floor is now open for questions. And first, we go to Gary Zwickenbaum with Palm Plumtree Consulting. Please go ahead. Thank you, Rick. John, welcome aboard. I wanna congratulate you as a team for fantastic quarter. And, you know, with the comments that you made on these orders of over a million dollars on the new agro agrochemical business, I a two part question. I'd like you, if you can, to discuss the effects of this new AgriChem business, not only for q three and q four, but as you alluded to, what would be 02/2022 and how you see it affecting profitability. And then if you would talk about the goals. I know, and recently, you mentioned the number of top goals that you have for the remainder of the year in '22. If you would just mention the important ones, the ones that you think we should be looking at. Thank you. Thank you, Gary. Thanks for the kind words. So your your first question is about the impact of the Agrochem to our financials going forward. We have gone out on the limb as they say. We have said we expect to have a significant impact in the third quarter. We've already purchased $05,000,000 of inventory. We've already received over $1,000,000 of orders for this material. So how much of that will be shipped in the third quarter is up in the air. But let's just say that I believe that between $500,000 and $1,000,000 somewhere in that. So maybe $607,800,000 dollars of that can be shipped in the third quarter and the rest we would expect to go into the fourth quarter. And also in several things we put out, I've mentioned that, we believe that the orders are going to continue to come. We're we're working on orders as we speak. And and, so the $1,000,000, we don't expect this to be the only set of orders for the second half of this year. So we're excited because this is additive to our existing core business. So you can look at our existing core business and add to that in the third and fourth quarter the $1,000,000 worth of orders. And I would say add some more to it because we expect that there'll be additional orders and that we can fulfill in the third and probably more the fourth quarter. And we're even looking at adding purchasing more bulk material that we will then be processing into finished goods in the next week or two. And so it's it's it's exciting. We're set up. I I'm just we're prepared for this. We have a facility. It is it is ready to receive. The bulk product is ready to process. It's ready to ship out. We are ready to go and we have the first set of purchase material and processing equipment and the ability to ship it out. So it will impact our third and fourth quarter. And and and this is we're doing this sort of, you know, very quickly. So I I'm I'm hopeful that next year, when we have more time to plan, we can do even better next year than pulling in a million or a million plus in a quarter or two. In fact, I think, our goal is to do much better than that next year. So again, transformational year, I think our investors, many of whom are on this call, are aware that we generally do $1,100,000 a quarter in our core business. I think our core business is going to be growing from that number. And on top of it, we're going to be adding at least, I think, the same amount, and certainly, we think next year, even more from our agrochem. John, would you like to add anything to that? I think I would just echo it. Having looked at this business and seeing the history of this agro this, eco friendly product, there is a significant pent up demand. I know a lot of people who own vineyards, and the wineries, by and large, especially the more boutique y, higher end out here in California, that they all are trying to be, eco friendly and totally natural. And so there's a great appeal in the grape industry of not using toxic chemicals. In fact, in order to garner the the label that you are actually, organic is very challenging, and it requires having products like these. So I'm I'm really excited, for the addition. And and, frankly, on the on the core business, we've seen return to the labs both in academic centers and in commercial. People are actually going back to their offices and using the equipment and are now really gearing up to expand their labs. They are looking at their budgets for the rest of the year. And so I'm cautiously optimistic that we continue to see the return to our core business of work. And then lastly, I've witnessed the transition in both UST and Verifold, where companies have gone from our first stage, which is proof of concept, and are moving into what we refer to as pilot scale. And and that's a a big transition because it that moves towards commercialization from which we can then benefit as a, as a partner, in a royalty sense. So, very exciting all around. Rick Rick, if I may, you mentioned, yesterday at the Emerging Growth Conference, and you alluded to it a few minutes ago, not only from the 500,000 in material that you recently purchased, but for the the million in orders that you had, you were gonna purchase additional materials. I think you talked about 300,000 plus possibly in the coming weeks and orders. How is this gonna affect 02/2022 and profitability? Can you expand on that a little? We've we've gone out on a limb and said we believe that we will become profitable as a company before the end of next year. Before the end of next year could be, you know, fourth quarter or it could be first or second quarter. But we believe that that this company is going to be profitable by the end of twenty twenty two and as soon as possible in 2022. It depends on the UltraShear, and it depends on the AgriPam and on and on on the Bareful. Our our PCT program is doing well. It's it did poorly the last couple of years, but it's it's it's we we can't keep enough product instruments in stock right now. It's it's a terrific problem to have. I'd much rather have a problem of how do I build more instruments and what do I do with these that I built six months ago. And that's the problem we have right now is how do we build more instruments to take care of this this demand, this pent up demand that's all of a sudden started, this year, and and, and it's real. And so, yes, we're we're looking forward to next year. The Agrochem business is a is a business that does high revenue and and has a good margin. And so with a high revenue and good margin, it should a lot of this should fall to the bottom line. And so that's why we feel comfortable in saying that we believe that this company will be profitable at some point next year with the combination of UltraShear and Agrochem. We will be in the Agrochem business. It's the eco friendly organic agrofend green, I should say, Agrochem business. But in the other many other areas where UltraShear can be used, we won't be competing with our our users. In those areas, we'll be making UltraShear available and looking for some type of continued stream of cash that's coming from the use of our incredible, UltraShear platform. And so with that, we've we've teamed up with Ohio State, and, and and things are going extremely well. And we're looking forward to getting Alt this year out and letting many other groups from many other industries use it. Rick and John, you you you should be commended, you and your team. I was visiting your office recently. What you've done in a short period of time with this new division is outstanding. I'm looking forward to the next two quarters and next year. Thanks a lot. Thank you. And and briefly, we're not gonna take up a lot of time, but Gary asked about the about the key. And I think they're important, so I'll just mention a few. I think we put out eight bullets on things that were key key goals of ours. But cleaning up the balance sheet is one. We've had we've had a tough time over the last few years. We've had to take a lot of onerous debt to keep things moving forward, and we've done a good job of cleaning that up over the last year, year and a half. Part of this has been cleaned up by the debt the debtors converting into stock, and part of it is by by taking on additional debt, and that additional debt is much better debt. You know, a lot of people say no debt's good, but a debt that is noted not not nearly as onerous as the debt we took is is better. And so we've taken on some debt and used that cash to pay off some of the more onerous debt. So our our balance sheet is is much cleaner than it was a year ago and much, much cleaner than it was two years ago. And our goal is over the next, really, couple of weeks to couple of months is to is to be, the only debt we want on the balance sheet is debt from some of the investors that we know are very strongly supportive of the company. And if we need them, to convert that debt into equity at some time, perhaps as a part of going on on a on a national exchange, These are the people that we're getting the debt from now. So we're cleaning up our balance sheet, and it's the same and we've reduced 3 or $4,000,000 of more onerous debt and replaced it with either using equity or or using much better, much more friendly debt to do that. Moving up to to Nasdaq or New York Stock Exchange is very high. Was this is a company that deserves and demands and needs to be on a national exchange. We need to have institutional support. We don't have a single institution in this company as an investor. We need that institutional support. We need that broad base that Nasdaq and New York Stock Exchange will bring to us. So it is a major goal. Remember, I started three prior companies that were all Nasdaq. This company was Nasdaq until we got delisted only because, our stock fell below a dollar. And it is our goal to get this company back on NASDAQ. And once we do that, I think the the wings can really open up and this company can have a great chance to fly. So it's a major goal of ours. We've got to finish the PBIO AgriChem and the acquisition of the assets of this other company that are just going to add to PBIO AgriChem. We've got to expand. We continue to expand our intellectual property. We've gotten five or six new patents in the last, year or so. Our partnership with Ohio State is gonna be very interesting come the fall because we have a a a a consortium with them, and, we're gonna we're shipping out our our our our prototype for industrial ultra sheer machine, and we're gonna be inviting, a who's who list from around the world to join the consortium and come and see and use their product and see how it works on our prototype. So there's so many of these things that and we've gotta get all this year out by the end of the year or early next year. So there's so many things that we have to do as a small company. It's it's it's guys like John who've drunk the Kool Aid and realized that this is a company that's transforming into a much different company going forward, coming on board to help me and help Jeff and help the team here. So, yeah, it's it's it's a great feeling that to have these goals and to know that they're all within reach. Next, we go to the line of Private Investor Tony Aggie. Please go ahead. Hi. Thanks for taking my call. I'm trying to make this very, very quick. You spoke about the patents and I was wondering, especially with the geopolitical situation as it is, you have patents and also business in China. Is that a possible concern? And also, do you have a strategy for those who are trying to short this company into the ground? Thank you. Well, thank you for the question, Tony. Number one, I'm not concerned about the issue you mentioned about the geopolitical issues that are going on. We do have business in China. It is not a large part of our business. We do have a major customer there who works with us. And through all of the the issues back and forth, he's continued to work. He and his team have continued to work with us. But I'm happy to say that China is important to us, but we're not dependent on China. We work with them. We work with them well. They work with us. And there's been no disruption from anything that's happened in the past with the group, the major group in China. But we are all over the place. We have very good strongholds throughout Europe, Eurasia, throughout Central And South America and Canada, of course, in The U. S. So no, I don't see that as an issue at all. In terms of you know, I can't really comment on on on the shorting. I know that I get phone calls every day, every week from investors who are concerned, who believe that the company, they look at how it it how it the activity is, and they believe that this company is being shorted. All I know, having started four publicly traded companies and been CEO of four publicly traded companies, actually three publicly traded companies on the board of the fourth, is that the best way to beat the shorts is to beat them with revenue and profits. And that's what we're gonna do. We are we are gonna transform this company. Whoever thinks that this company is a company that they've been beaten up, you know, for the last two, three, four, five years, they're gonna be shown that they're wrong. This company is ready to break out. We've laid it out. We're very clear, and we're very confident. And we believe very strongly that it begins now. The transformation has already started. So, Tony, I won't talk about shorting because it's not something that I know much about. I just know how to beat shorts, and you beat shorts by delivering what investors expect us to deliver and that's what we believe we're going to be doing and starting already. Thank you, Rick. I'm happy to hear that. Next, we have another private investor, Martin Joseph. Your line is open. Yes. Hi. Thanks for the call. I have questions related to, say, the astaxanthin and any other products that you might want to be pursuing. With that. In the companies that you're reaching out to, do you find that it's, the the greater bioavailability that's, the appeal to them or potentially using, say, less product? I'm I'm a, I guess, you can call premium supplement user. So, you know, looking at my astaxanthin, now there's six milligrams in there. So, obviously, it's not as bioavailable bioavailable. So would are companies looking to then reduce, but then, say, have a branded sort of product, astaxanthin, that they would market to say, hey. You only need two milligrams of this? Or are are they thinking they'll still keep the six, but then they'll market the you're getting more for that six than you need from another company? It's a great question for John. So I'm going to turn it over to John. John's been right in the front of the line talking to all of the companies that are calling us and a lot of them have about astaxanthin and other compounds. Yeah. Thank you for turning over. It's also a great question. And I have to answer it as this. I've had different attributes that people are pursuing from different companies. That's with Anthem because it is actually relatively expensive. The cost of the goods sold, if you can limit or reduce the amount you need to achieve the same goals. And I think secondarily and importantly, if you're in the business, appreciate this, have a predictable dose. Because many of these oils, when metabolized or broken down in the gut, are metabolized in different rates by different people. And so you really don't have the same dose for each person. Theoretically, or at least the data suggests that when you make an annual emulsion of these oils, you can actually much more deliberately, deliver the dose that you wanna deliver. The third attribute that I have found with astaxanthin, as well as CBD and several other products that we made in Animal Emotions is the aesthetics. Because especially if whatever form the final product is, if it's a clear product, it's really nice to put in a clear active agent, and and that's what we can do up to certain concentrations, but these concentrations seem to be adequate. So it it's not one particular attribute. It's different for different players. So I think that's the best way to describe it. Thank you very much. Next, we go to the line of Jeffrey Scott with Scott Asset Management. Please go ahead. Rick, it's been a long time since we had that lobster roll today. It has. I I hope you've been well. It's been tough out there. It has. I'd like to drill down on the the Agrochem and get away from from kind of big numbers and talk about specific details. The million dollars in orders, how many different products is that is that million dollars of orders for? How many different customers? Is it one order from one customer for a million dollars worth of goods, or is it 10 orders for a hundred thousand each from 10 different customers? Is it going to commercial growers, or is it meant to be distributed through house and garden retail stores for use in in a consumer's backyard garden? That kind of detail, help us out with some of those nitty gritty details, please. I will a little bit, Jeff, and I'm not gonna get into too too much of the weeds here. But I'll tell you, first of all, it it's more in bulk with large growers right now. But we have, we have plans to go to more retail. The you know, generally, in most cases, you know, retail is is more lucrative than than bulk to to large growers. And so we do some retail. In fact, we've already shipped some product, I think, two or three to retailers. But the the bulk product is is generally what we're gonna be doing. So it's not gonna be a hundred customers at, you know, $10,000 apiece. It's gonna be more like five to 10 customers at a 200,000 apiece in that range. So without getting into the nitty gritty, I I think right now, it's gonna be larger amounts going to bigger users, But we have our eye on the small retail customer because that is, you know, that's where the it can get very lucrative. We can provide a product that's much needed. And and and and the same product, the same cost, we can get we can get more of a payback for it. John, you wanna add to that? Sorry about that. Yeah. I was stuck on mute there for a moment. Yeah. The AgriChem business, as you may or may not know, is driven and dominated by some very large distributors who are through the central values of the growing areas that then distribute to large agribusiness and small farms, the combination of the two. And so those agricultural distributors are definitely familiar with this product, and we look to see them as the customers. But there's also a a second group, and almost it's as if you use either direct sale or drop ship sale, these very large volume, literally thousand liter totes of chemicals that are either sprayed through the water systems or sprayed on top of the plants, depending on which product it is. To Rick's point, we see a portion of the business in consumer oriented products, which definitely are at higher value or higher margins to us. But the, large bulk shipments are going to be, at least for the first couple of years, the core of our business. Very large shipments in 18 wheel trucks that drive it out either directly to the farm or directly to the distributor. I hope that helps. Yeah. That's helpful. That million dollars of orders, is that for one product, or is that do you have multiple products that are going out? There's there's several products in there, but it's it's not like 20 products. You know, the growing season and what's growing is is different all the time. And so some of the products are are needed now. Some of the products are needed in November. Some of the and that's good because we don't wanna be seasonal where majority of our agrochemical products are all sent in, you know, in a three month period. So we have products for every season. And so you'll you'll see that, you know, this season right now that we're going into will have its own set of products that's needed. And then the next season will need its own set of products. And we have we have products that are already made, some of which we think we can make in the future even better, make good things even better for each of the seasons that come. So whether it's, you know, corn or or or soybeans or or grapes or whatever it is, we hope to have products being shipped out basically twelve months a year. Alright. And can you tell us exactly what the product what the product does? I'll tell you what, Jeffrey. An an an insecticide or herbicide, what what kind of benefit does it give that grower? We have both. We have fertilizers. We have pesticides that are all eco friendly. So it's a combination. But, you know, I'm not trying to evade your question. We're just we're in the we're we're in the middle or not we're near the end of negotiations with certain people, so we wanna we gotta keep some things close to the vest. I I know you understand that. So, perhaps in in our call in three months, we can be, you know, maybe even take you down the product line itself, so to speak. But right now, we we can't do that. We have a lot of IP that's that's based on this, which is trade secret driven and not patents driven. And, you know, so we wanna be careful what we say because we haven't finished the acquisition, but we're doing some of those work ourselves right now. So when you think about the, you know, the gross stimulants that we put this into a couple press releases, the pest treatment, things like that, finishing products that are going on to things like grapes or or other plants or other other fruit. So it's a combination, which is good because it gives makes it much more broad based. Okay. Good luck. I will hold my breath for another three months. Thanks, Rick. Thank you. Yeah. You're very patient, Jeffrey, and we appreciate it. Okay. That does appear to be all the signals we have today. So we'll turn back to Rick Schumacher for closing remarks. First of all, John, thank you for joining us, and I'm glad that our investor base was able to meet you and and see your very impressive background and know that you're part of the team now, which is very helpful to me in particular because there a day doesn't go by where I don't pick up the phone and say, John, I I need you to help me out on this. It's great to have someone who's gone through what I go through as a CEO and especially CEO of a public company. So, John, publicly, in front of everyone, thank you very much, and don't think about starting your own thing for the time being. And for everybody else, just thank you for taking time. And as you know, I'm always available at the other end of the phone. This is an exciting time. You know, I I I think the the old phrase, the best is yet to come. It's in our case, we believe it's absolutely true. We've We've had a terrific two quarters. We had a tough year last year. We've had a tough two or three years for different reasons, but we've had a great start to 2021. We believe we're going to have a much better ending, and it's always great when you have a better ending to a great start. We think this is our transformational year. We think we've we believe that all the things that we put into motion over the last few years are are coming to fruition. And then on top of it, you know, the icing on the cake is this opportunity in in Agrochem, which, which, we have taken advantage of. So, exciting times. It makes it it makes it easy to to go to bed late and get up early and come into work because it is it's it's all moving in the right direction. And everybody on this phone call who's in a an investor has has every right to you've been patient. Those of you who've been with us for years, and I know some of you have, you've been very patient and we're working very, very hard, to get a return for everybody, the new investor and especially the investor that's helped us out for years now. Thank you. Thank you. This does conclude today's teleconference. We thank you for your participation. You may disconnect your lines at this time. Have a great day.